Cyclacel Pharmaceuticals, Inc. — Cyborg Score 4/10
Mixed
Oncology Drugs
Strategic Profile
Lead products include fadraciclib, a cyclin dependent kinase inhibitor (CDK) in Phase 1/2 clinical trial for solid tumors and in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia, and Plogosertib, a polo-like kinase inhibitor program in Phase 1/2 clinical trial for advanced leukemias and solid tumors. The company pursues a mechanism-targeted approach to oncology drug development.
Cyborg Score Rationale
Cyclacel is in early-to-mid clinical stages with two lead programs showing early promise. The company's cell cycle and epigenetics platform is scientifically sound, but execution risk is high given the competitive oncology landscape and limited disclosed capital. Data conflicts on current public/private status add uncertainty.
Top Insights
Fadraciclib Phase 1 data suggests selective efficacy in tumors with CDKN2A/2B or MTAP deletion—potentially enabling precision oncology positioning
Dual-program approach (CDK inhibitor + PLK1 inhibitor) mitigates single-asset risk but requires sustained capital deployment
Founded in 1996 but remains clinical-stage, suggesting extended development timelines and execution challenges in oncology
Current public/private status unclear as of June 2026; delisting or transition to private status possible but unconfirmed in available data
Named Competitors
Palbociclib (Ibrance) — Approved CDK4/6 inhibitor for breast cancer
Ribociclib (Kisqali) — Approved CDK4/6 inhibitor for hormone receptor positive breast cancer
Venetoclax (Venclexta) — BCL2 inhibitor approved for CLL and AML
Recent Developments
Phase 1 results announced for fadraciclib in advanced solid tumors and lymphomas showing activity in patients with specific protein deletions (CDKN2A, CDKN2B, MTAP)
Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer (October 2020) with 30+ years oncology/hematology experience
Open the full interactive Cyclacel Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.